<DOC>
	<DOC>NCT01145352</DOC>
	<brief_summary>This surveillance is conducted to survey the followings under the post marketed drug utilization on the patients who are administrated ENBREL as a treatment for active polyarticular JIA. 1. Primary Occurrence status of Adverse Events; incidence of all adverse events, serious adverse events 2. Secondary Factors affecting safety and to confirm the efficacy such as DAS28.</brief_summary>
	<brief_title>Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance]</brief_title>
	<detailed_description>All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis during registered period (2.5 year).</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Juvenile</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Patients in active polyarticular JIA (restricted to the case of lack of effect by other treatment) during enrollment period (2.5years). Patients receiving Enbrel for JIA as diagnosed by a qualified physician. Age 5 16 years Patients not administered ENBREL</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Enbrel-JIA</keyword>
</DOC>